SecBot SecBot

GILD drug pipeline

GILEAD SCIENCES, INC. · 10 rated drugs
$167.58
−0.3% 1-day · Nov 16
Next catalyst
Dec 23, 2026
anito-cel PDUFA date · in 37 days
Typical move on FDA news
±1.5%
1-day, median of 25 events
IV rank
55
IV 31% · HV 31%
Rated drugs
10
2 bullish · 8 neutral
Phase 3 trials
15
6 with results posted

Upcoming catalysts

7 dated
  1. Nov 2026
    CAL101
    Phase 2 primary completion
  2. Dec 23, 202637d
    anito-cel
    PDUFA date · relapsed or refractory multiple myeloma (4L+)
  3. Dec 2026
    anitocabtagene-autoleucel
    Phase 2 primary completion
  4. Jan 2027
    Tilpisertib Fosmecarbil
    Phase 2 primary completion
  5. Feb 2, 202778d
    Yeztugo
    NDA filing · HIV pre-exposure prophylaxis
  6. Feb 2, 202778d
    Yeztugo
    PDUFA date · HIV pre-exposure prophylaxis
  7. Feb 2027
    Trodelvy
    Phase 3 primary completion

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseFiled/BLA under FDA review (PDUFA December 23, 2026)
Time to marketIf approved, commercial launch could begin in early 2027 following the December 23, 2026 PDUFA date. Gilead has stated launch preparations are underway.

anito-cel anitocabtagene autoleucel Updated Oct 30

37days
Next catalyst
PDUFA date · Dec 23, 2026 · relapsed or refractory multiple myeloma (4L+)
What to watch

The single most important catalyst is the FDA PDUFA decision on December 23, 2026. An approval would likely drive GILD shares higher as it validates the $7.8B Arcellx acquisition and adds a potentially best-in-class CAR-T to Gilead's oncology portfolio. A Complete Response Letter (rejection) would be a significant negative, though the strong efficacy and clean safety data from iMMagine-1 and the Phase 1 NEJM publication reduce that probability. Watch for any FDA Advisory Committee meeting announcement between now and December, which would add an additional binary event.

Bull case
  • iMMagine-1 data showed a 96% overall response rate and 74% stringent complete response rate, among the highest seen in heavily pretreated multiple myeloma
  • Phase 1 NEJM publication reported 100% response rate and 79% complete response in 38 patients, with no delayed neurotoxicity
  • Matching-adjusted indirect comparison at IMS 2026 showed anito-cel matched Carvykti's efficacy with significantly lower rates of CRS, ICANS, and non-relapse mortality
Bear case
  • The BLA is based on a single-arm Phase 2 study (iMMagine-1) with no randomized comparator, which may raise FDA scrutiny on the benefit-risk assessment
  • Carvykti (J&J/Legend) is already approved in earlier lines (2L+) and has a significant head start in market share and physician familiarity
  • CAR-T manufacturing remains complex and capacity-constrained; anito-cel must compete for manufacturing slots with Gilead's own Yescarta and Tecartus
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2016 (HIV treatment) and 2019 (PrEP).

Descovy emtricitabine and tenofovir alafenamide Updated Oct 29

What to watch

Descovy has no upcoming binary catalyst of its own; it is a mature cash-flow product within Gilead's broader HIV franchise. The next major Gilead catalyst is the anito-cel PDUFA date on December 23, 2026, which is unrelated to Descovy. Watch for quarterly sales trends, particularly any cannibalization from Gilead's own Yeztugo (lenacapavir) and the impact of generic Truvada competition on PrEP pricing.

Bull case
  • Descovy Q3 2026 sales surged 49% year-over-year to $1.0 billion, driven by higher average realized price and strong demand, per Gilead's Q3 2026 earnings release.
  • Gilead's PrEP franchise (Descovy + Yeztugo) topped $1 billion in quarterly sales for the first time in Q2 2026, demonstrating strong market growth.
  • Descovy has a differentiated safety profile versus older Truvada (less kidney and bone toxicity), supporting its position in the PrEP market.
Bear case
  • Descovy faces internal cannibalization from Gilead's own Yeztugo (twice-yearly lenacapavir injection for PrEP), which is positioned to eventually surpass Descovy as the company's lead PrEP product.
  • Generic Truvada is available at $27-$70 per month, creating significant pricing pressure on brand-name Descovy (approximately $2,392/month list price).
  • Primary US patents on Descovy have expired or are expiring, with some sources estimating generic entry could occur as early as 2027-2031 depending on litigation outcomes.
● neutral
Impact
PhasePhase 2
Time to marketIf Phase 3 begins in 2027, a typical 12-18 month enrollment and follow-up period would put Phase 3 readout around 2028-2029, with potential FDA filing around 2029-2030 at the earliest, assuming positive results.

Emvistegrast Updated Oct 30

What to watch

The Phase 2 data is now public (October 19, 2026). The next catalyst is the planned Phase 3 monotherapy study initiation in 2027, which is not a hard binary event. Investors should watch for the Phase 3 trial design details, enrollment timelines, and any expansion into Crohn's disease or combination regimens. The key competitive watchpoints are Eli Lilly's oral alpha4/beta7 inhibitor zotemtegrast (Phase 2) and Takeda's Entyvio franchise facing biosimilar erosion.

Bull case
  • Phase 2 data showed strong efficacy: 66% clinical response and 31% remission at 12 weeks with 200mg dose, both statistically significant versus placebo
  • Oral once-daily formulation offers major convenience advantage over injectable Entyvio, which requires IV infusion, potentially expanding the treatable patient population
  • Cross-trial comparison suggests emvistegrast's 31% remission rate may exceed Entyvio's ~17% remission rate in its Phase 3 trials
Bear case
  • Emvistegrast is still early-stage (Phase 2); Phase 3 trials can fail even after promising Phase 2 results
  • Competition is intensifying: Eli Lilly's oral alpha4/beta7 inhibitor zotemtegrast (formerly MORF-057) is also in Phase 2 development for UC
  • Longer-term safety and maintenance data are not yet available; the Phase 2 study only covered 12 weeks of induction
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (Sunlenca since December 2022; oral tablet and Bixlenvo combo approved August 2026)

lenacapavir lenacapavir sodium Updated Oct 24

What to watch

Lenacapavir's binary catalysts (original approval, Bixlenvo combo approval) have already passed. The next potential catalyst is Phase 2 PrEP data (HPTN 102, primary completion July 2026), but no topline readout has been announced. For GILD investors, the focus should be on commercial uptake of Sunlenca and Bixlenvo in upcoming quarterly earnings, not a single binary event.

Bull case
  • Lenacapavir is a first-in-class HIV capsid inhibitor with a unique twice-yearly dosing advantage over daily oral pills, addressing adherence challenges in HIV treatment and potentially PrEP.
  • The FDA approved both a supplemental oral tablet (Sunlenca) and the Bixlenvo combo (bictegravir/lenacapavir) in August 2026, expanding the addressable patient population beyond multi-drug-resistant HIV.
  • GILD has strong institutional support with BlackRock ($15.4B), Vanguard ($10.2B), and FMR ($8.4B) as top holders as of Q2 2026.
Bear case
  • Lenacapavir faces entrenched competition from Gilead's own Biktarvy (the market-leading HIV regimen) and other oral daily HIV therapies, which may limit Sunlenca/Bixlenvo uptake to niche multi-drug-resistant patients.
  • The Phase 3 trial (NCT06613685) of an oral weekly combination including lenacapavir was terminated, raising questions about the oral weekly formulation strategy.
  • Insider selling by the CEO, CFO, and other executives in recent months (all under 10b5-1 plans) signals no urgency to accumulate shares near the 52-week high.
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercially launched in the US (August 2024) and EU (2025).

Livdelzi seladelpar Updated Oct 29

What to watch

Watch for any announcement regarding conversion of Livdelzi's accelerated approval to traditional approval based on the positive IDEAL trial data, which could serve as a label-strengthening catalyst. Also monitor quarterly liver disease portfolio sales trends for Livdelzi's commercial trajectory, particularly as it captures share following Ocaliva's US market withdrawal. The next hard catalyst for Gilead overall is the December 23, 2026 PDUFA for anito-cel (a different drug), not Livdelzi.

Bull case
  • Strong clinical data: Livdelzi achieved statistically significant ALP normalization in two Phase 3 trials (RESPONSE and IDEAL), with a favorable safety profile and demonstrated pruritus relief.
  • Commercial momentum: Liver disease portfolio sales reached $927M in Q3 2026, up 13% YoY, driven by Livdelzi demand. Gilead raised full-year base business guidance in October 2026.
  • Competitive advantage: The older competitor Ocaliva (obeticholic acid) was withdrawn from the US market in November 2025, removing a major rival and potentially expanding Livdelzi's addressable market.
Bear case
  • Accelerated approval status: Livdelzi's US approval is conditional on confirmatory data demonstrating clinical benefit (improvement in survival or prevention of liver decompensation), which has not yet been proven.
  • Competition from Iqirvo: Ipsen's elafibranor (Iqirvo) also received accelerated FDA approval in June 2024 for the same second-line PBC indication, creating direct head-to-head competition for market share.
  • Pricing and reimbursement pressure: As a second-line therapy in a rare disease, Livdelzi faces ongoing payer scrutiny and prior authorization requirements that could limit uptake.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2020

Trodelvy sacituzumab govitecan Updated Oct 24

What to watch

Trodelvy is a commercial-stage asset at Gilead with no near-term binary catalyst, investors should watch for label-expansion data readouts (e.g., Phase 2 NSCLC results) and quarterly sales trends rather than a single make-or-break event. The BioNTech collaboration is a non-financial supply agreement with data years away; it does not change Gilead's near-term outlook.

Bull case
  • Trodelvy is a first-in-class Trop-2 ADC with three approved indications and a growing body of clinical data supporting label expansion into NSCLC and other solid tumors.
  • Gilead's strong commercial infrastructure and oncology sales force support continued Trodelvy revenue growth; the drug is a key pillar of Gilead's diversification beyond HIV.
  • Analyst consensus on GILD is strongly bullish, 30 Buy/Strong Buy, 7 Hold, 0 Sell, with a mean price target of ~$160, implying ~5.7% upside from the current ~$156.
Bear case
  • Trodelvy faces intensifying competition from other ADCs, notably Enhertu (trastuzumab deruxtecan) in breast cancer and datopotamab deruxtecan (Dato-DXd) from AstraZeneca/Daiichi Sankyo, which could erode market share.
  • The urothelial cancer indication faced headwinds, the confirmatory Phase 3 TROPiCS-04 trial completed but the accelerated approval pathway has been challenging.
  • Trodelvy is a single product within a large, diversified Gilead portfolio (~$156B market cap); even significant label expansion would have a modest impact on GILD's overall valuation.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since October 2017.

Yescarta axicabtagene ciloleucel Updated Oct 30

What to watch

Yescarta has no scheduled PDUFA date or pivotal readout in the next 12 months. The next catalyst to watch is the Q4 2026 earnings release (late January/early February 2027) for the sales trajectory and any commentary on competitive dynamics versus Breyanzi and Carvykti. Longer term, watch for any data from Kite's next-generation CAR-T programs or label expansion studies that could reverse the sales decline.

Bull case
  • Yescarta is a first-in-class, first-to-market CAR-T therapy for LBCL with a well-established safety and efficacy profile across multiple indications.
  • The ZUMA-7 trial showed a statistically significant overall survival benefit versus standard of care, strengthening the drug's clinical positioning as second-line therapy.
  • The February 2026 FDA label update removing PCNSL limitations of use opens access to a new patient population with a rare and aggressive lymphoma.
Bear case
  • Yescarta sales are declining: Q3 2026 revenue fell 16% year-over-year to $294 million, with Q2 2026 down 12% and Q1 2026 down 14%, driven by in- and out-of-class competition.
  • The CAR-T competitive landscape is increasingly crowded with at least five approved CD19-directed products in the US/EU (Breyanzi, Kymriah, Tecartus, Aucatzyl) plus emerging Chinese competitors.
  • Bristol Myers Squibb's Breyanzi has been expanding into earlier lines of therapy, directly competing with Yescarta's second-line LBCL indication.
● neutral
Impact
PhaseApproved
Time to marketAlready marketed (FDA approved March 2016).

Odefsey emtricitabine / rilpivirine / tenofovir alafenamide Updated Oct 30

What to watch

Odefsey has no upcoming binary catalyst; the next material event for the drug would be generic entry risk around 2033. Gilead's stock is driven by the broader HIV franchise (led by Biktarvy), oncology drug Trodelvy, and pipeline developments like the islatravir/lenacapavir once-weekly HIV regimen partnered with Merck. Watch Gilead's quarterly HIV sales breakdown and any Paragraph IV patent settlement updates for Odefsey.

Bull case
  • Odefsey is a well-established, FDA-approved single-tablet HIV regimen with a decade of real-world use and safety data.
  • Gilead's HIV franchise is firing on all cylinders: Q3 2026 HIV sales rose 18% YoY to $6.249B, and Biktarvy reached an all-time high U.S. market share of 53%.
  • Patent protection extends to approximately 2033, providing a long runway of exclusivity against generic competition.
Bear case
  • Odefsey is a mature product facing competition from newer, more convenient HIV regimens, particularly Gilead's own Biktarvy, which dominates the market.
  • A Paragraph IV patent challenge has been filed against Odefsey's patents, creating risk of earlier-than-expected generic entry.
  • MassHealth (Massachusetts Medicaid) began requiring prior authorization for Odefsey as of January 2026, potentially restricting access.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US (initial approval July 2020, full approval April 2026) and EU (EMA approval 2021).

Tecartus brexucabtagene autoleucel Updated Oct 30

What to watch

Tecartus has no upcoming binary catalyst; the next major Gilead cell-therapy catalyst is the anito-cel PDUFA date on December 23, 2026, for relapsed/refractory multiple myeloma. Watch for further Tecartus sales erosion in Q4 2026 earnings (late January/early February 2027) and any potential earlier-line trial data that could reverse the decline.

Bull case
  • Tecartus was the first and remains the only CAR-T therapy approved for mantle cell lymphoma, a rare and aggressive blood cancer with high unmet need.
  • Full FDA approval was granted in April 2026 based on ZUMA-2 Cohort 3 confirmatory data showing a 91% overall response rate, validating the drug's efficacy.
  • The FDA eliminated the REMS (Risk Evaluation and Mitigation Strategy) requirement for Tecartus in June 2025, reducing post-market regulatory burden and potentially easing access.
Bear case
  • Sales are declining sharply: Tecartus revenue fell 28% YoY to $60M in Q3 2026, down from $75M in Q1 2026 and $70M in Q2 2026, driven by in-class competition from other CD19 CAR-T therapies (Breyanzi, Kymriah, Aucatzyl).
  • The CD19 CAR-T space is the most crowded cell-therapy market, with at least six approved products in the US/EU competing for similar patient populations.
  • Tecartus is a small and shrinking part of Gilead's overall business (less than 1% of Q3 2026 product sales of $8.3B), limiting its ability to move the stock.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since October 2020.

Veklury remdesivir Updated Oct 30

What to watch

Veklury has no upcoming binary catalysts and is a negligible part of Gilead's business. For GILD investors, the focus should remain on the HIV franchise (which grew 18% in Q3 2026), the oncology portfolio including Trodelvy, and the newly launched twice-yearly PrEP drug Yeztugo. Veklury's continued revenue decline is already well-telegraphed and priced in.

Bull case
  • Veklury remains a standard-of-care IV antiviral for hospitalized COVID-19 patients and is recommended by the CDC as a second-line treatment option for high-risk outpatients, maintaining a steady if shrinking revenue base.
  • Gilead's overall business is strong: Q3 2026 product sales rose 13% YoY to $8.3 billion, base business grew 16%, and the company raised full-year guidance three times in 2026.
  • The stock has strong analyst support with 30 Buy/Strong Buy ratings versus 7 Hold and 0 Sell, and a composite quant score of 52 with improving earnings revisions.
Bear case
  • Veklury sales are in structural decline: Q3 2026 revenue of $86 million was down 69% year-over-year, and full-year 2026 guidance was slashed from $600 million to roughly $300 million due to lower COVID-19 hospitalization rates.
  • Oral competitors like Pfizer's Paxlovid offer more convenient at-home treatment, eroding Veklury's addressable market.
  • Veklury now represents roughly 1% of Gilead's total product sales, making it essentially immaterial to the investment thesis for the stock.

Other drugs in filings and trials

no drug report yet
  • Yeztugo Next: NDA filing · Feb 2, 2027 Last: Approval · Jun 18, 2025
  • BIC LEN Last: Priority review · Aug 27, 2026
  • bictegravir and lenacapavir (BIC LEN) Last: PDUFA decision · Aug 27, 2026
  • Hepcludex Last: Accelerated approval · Jan 1, 2026
  • EPCLUSA Last: Approval · Jun 10, 2021 1 trial
  • SOVALDI Last: Approval · Aug 28, 2019
  • BIKTARVY Last: Approval · Feb 7, 2018
  • VOSEVI Last: Approval · Jul 18, 2017
  • VEMLIDY Last: Approval · Nov 10, 2016
  • GENVOYA Last: Approval · Nov 5, 2015
  • HARVONI Last: Approval · Oct 10, 2014
  • TYBOST Last: Approval · Sep 24, 2014
  • ZYDELIG Last: Approval · Jul 23, 2014
  • STRIBILD Last: Approval · Aug 27, 2012
  • VIREAD Last: Approval · Jan 18, 2012
  • anitocabtagene-autoleucel 1 trial
  • CAL101 1 trial
  • CLEVUDINE IN ASSOCIATION TENOFOVIR 1 trial
  • co-formulated 25mg TAF/ 200mg FTC 1 trial
  • Descovy or Truvada 1 trial
  • Edecesertib 1 trial
  • emtricitabine / tenofovir disoproxil fumarate / raltegravir . 1 trial
  • Filgotinib 2 trials
  • Obeldesivir 2 trials
  • sofosbuvir/velpatasvir 2 trials
  • Tilpisertib Fosmecarbil 1 trial

Past FDA events & how the stock moved

25 events
DateDrugEvent1 day5 days
Aug 27, 2026bictegravir and lenacapavir (BIC LEN)PDUFA decision−1.6%+2.1%
Aug 27, 2026BIC LENPriority review−1.6%+2.1%
May 7, 2026TecartusApproval−3.6%−3.1%
Apr 28, 2026anito-celFast Track+0.8%+4.5%
Apr 28, 2026anito-celOrphan drug designation+0.8%+4.5%
Jan 1, 2026HepcludexAccelerated approval−0.9%−1.7%
Jun 18, 2025YEZTUGOApproval+0.5%−0.3%
Aug 14, 2024LivdelziApproval+0.5%+1.6%
Dec 22, 2022lenacapavirApproval−0.6%+0.7%
Jun 10, 2021EPCLUSAApproval+0.2%−1.1%
Oct 22, 2020VekluryApproval+1.0%−2.8%
Aug 28, 2019SOVALDIApproval+0.7%+1.2%
Feb 7, 2018BIKTARVYApproval−2.7%+1.8%
Jul 18, 2017VOSEVIApproval+2.2%+3.6%
Nov 10, 2016VEMLIDYApproval−2.6%−3.7%
Jun 28, 2016EPCLUSAApproval+5.1%+9.6%
Apr 4, 2016DescovyApproval+1.5%+1.8%
Mar 1, 2016OdefseyApproval+1.8%+1.6%
Nov 5, 2015GENVOYAApproval−0.6%−4.4%
Oct 10, 2014HARVONIApproval−4.2%−4.8%
Sep 24, 2014TYBOSTApproval+1.9%+0.2%
Jul 23, 2014ZYDELIGApproval+1.4%+5.0%
Dec 6, 2013SOVALDIApproval+2.7%−2.5%
Aug 27, 2012STRIBILDApproval+0.6%+1.3%
Jan 18, 2012VIREADApproval+2.0%+4.4%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
TrodelvyStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerPhase 3Active not recruiting443Feb 2027
Tilpisertib FosmecarbilStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisPhase 2Active not recruiting176Jan 2027
anitocabtagene-autoleucelStudy of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Phase 2Active not recruiting136Dec 2026
CAL101A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisPhase 2Active not recruiting150Nov 2026
FilgotinibFilgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisPhase 3Completed1,173Sep 8, 2026
TrodelvyStudy of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)Phase 2Active not recruiting193Sep 2026
DomvanalimabStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01Phase 2Active not recruiting100Aug 2026
Lenacapavir TabletStudy of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)Phase 2Active not recruiting253Jul 2026
sofosbuvir/velpatasvirExpanding the Pool in Orthotopic Heart TransplantationPhase 2Completed20Jun 2, 2026
LivdelziIntended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)Phase 3Completed96May 6, 2026
TecartusStudy Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin LymphomaPhase 2Completed95Mar 25, 2026
lenacapavirStudy of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedPhase 3Terminated73Mar 16, 2026
Descovy or TruvadaSmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use DisorderPhase 3Completed40Feb 27, 2026
EdecesertibStudy of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)Phase 2Terminated20Dec 17, 2025
YescartaStudy of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell LymphomaPhase 2Completed · results35Nov 24, 2025
EpclusaA Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney RecipientsPhase 2Completed201Jul 15, 2025
TrodelvyStudy of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadPhase 3Completed · results711Jul 4, 2025
TecartusStudy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)Phase 2Completed · results95Jun 17, 2025
FilgotinibLong Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid ArthritisPhase 3Completed · results2,731May 16, 2025
ObeldesivirStudy of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) InfectionPhase 2Terminated · results150May 8, 2025
ObeldesivirStudy of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) InfectionPhase 2Terminated · results4Apr 16, 2025
sofosbuvir/velpatasvirThe Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant RecipientsPhase 2Completed · results5Mar 17, 2025
TecartusStudy of Brexucabtagene Autoleucel in Adults With Rare B-cell MalignanciesPhase 2Terminated · results19Jan 27, 2025
TrodelvySacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder CancerPhase 2Terminated · results4Oct 15, 2024
co-formulated 25mg TAF/ 200mg FTCThe Women TAF-FTC Benchmark StudyPhase 3Completed · results54Dec 19, 2023
TecartusStudy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)Phase 2Completed · results105Sep 22, 2023
VekluryTrial of Treatments for COVID-19 in Hospitalized AdultsPhase 3Completed1,552Jul 9, 2022
IdelalisibA Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLPhase 2Completed · results27Oct 6, 2020
Cabotegravir Oral TabletInjectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With MenPhase 3Completed · results4,570May 14, 2020
F/TAFStudy to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 InfectionPhase 3Terminated · results5,399Jan 31, 2019
SofosbuvirImpact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCCPhase 3Completed150Dec 2017
emtricitabine / tenofovir disoproxil fumarate / raltegravir .Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected PatientsPhase 2Completed · results30Dec 2015
ArhalofenateEvaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With GoutPhase 2Completed32Dec 2014
ArhalofenateSafety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With GoutPhase 2Completed67Nov 2011
MBX-2982Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 DiabetesPhase 2Completed100Aug 2010
MBX-102Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on MetforminPhase 2Terminated242Feb 2010
CLEVUDINE IN ASSOCIATION TENOFOVIRANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB TherapyPhase 3Terminated150Dec 14, 2008
VekluryTrial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 InfectionPhase 3Terminated · results—Not stated
FilgotinibStudy to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious UveitisPhase 2Terminated · results—Not stated
emtricitabine, FTC (drug)Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAARTPhase 3Completed350Not stated